All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On the 17th February 2017 Tandon et al. from The Mayo Clinic, Rochester, USA, published an article in Blood which examined the benefits of using the Revised International Staging System (RISS) (for both newly diagnosed (ND) and relapsed/refractory (R/R) Multiple Myeloma (MM) patients) for improved prognosis and stratification into survival groups.
The authors also examined OS and PFS differences between patients diagnosed between 2005 and 2010, compared with those diagnosed between 2011 and 2015. They did observe some improvement in RISS between stages, but the difference was not statistically significant. The same variables used to determine RISS stage were given equal weight and used to generate a prognostic risk score for both cohorts. This also proved successful in stratifying patients with both NDMM and RRMM.
The RISS was devised using only data from patients enrolled in clinical trials and allows for an improved prognosis and better separation of patients (both NDMM and RRMM) into survival subgroups, by combining data from chromosomal abnormalities (CA) and serum lactate dehydrogenase (LDH), with ISS score. This scoring system also has clinical utility outside a clinical trial setting and could be used to classify patients for more customized treatment regimes.
We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox